Stockscreener 앱 받기
1.1921
15.74%
0.1621
시간 외 거래:
1.13
-0.0621
-5.21%
전일 마감가:
$1.03
열려 있는:
$1.02
하루 거래량:
164.68K
Relative Volume:
1.03
시가총액:
$79.14M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.84%
1개월 성능:
+0.18%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.02
$1.20
1주일 범위
$1.01
$1.27
52주 변동 폭
$0.925
$2.87
Citius Oncology Inc Stock (CTOR) Company Profile
명칭
Citius Oncology Inc
전화
(347) 627-0058
주소
420 LEXINGTON AVE,, NEW YORK
Citius Oncology Inc 주식(CTOR)의 최신 뉴스
CTOR stock touches 52-week low at $1.02 amid market challenges - Investing.com India
CTOR stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
CTOR stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa
CTOR stock touches 52-week low at $1.29 amid market challenges - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com
Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex
Cytek BioSciences Inc (CTKB)’s stock performance: a year in review - US Post News
Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's
Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex
XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World
CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada
CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - Nasdaq
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow
A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News
Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com
Citius Oncology Inc. (CTOR) requires closer examination - US Post News
Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks
CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle
Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.00, Reflecting a -11.11 Downturn - The Dwinnex
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia
Citius Oncology Inc. completes strategic acquisition - Investing.com
Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ
Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.47, Reflecting a -22.81 Downturn - The Dwinnex
Citius merges oncology subsidiary with TenX Keane - Yahoo Finance
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Quantisnow
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - StockTitan
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - ForexTV.com
TenX Keane addresses trading halt, continues toward combination closing - TipRanks
New Ontak on track as Citius wins FDA’s nod for Lymphir in CTCL - BioWorld Online
US FDA approves Citius' therapy for rare blood cancer - Reuters.com
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - PR Newswire
Biotech Alert: Searches spiking for these stocks today - TipRanks
Citius Pharmaceuticals Advances Oncology Spinoff Through Merger with TenX Keane - Vancity Buzz
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology - Nasdaq
Citius Pharma secures majority in TenX merger deal - Investing.com India
Citius Pharma secures majority in TenX merger deal By Investing.com - Investing.com Australia
Citius Oncology Inc (CTOR) 재무 분석
Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.88%
0.42%
자본화:
|
볼륨(24시간):